Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Managing anemia with epoetin alfa in patients with rectal cancer
Authors:ID Velenik, Vaneja (Author)
ID Oblak, Irena (Author)
ID Kodre, Veronika (Author)
Files:.pdf PDF - Presentation file, download (135,72 KB)
MD5: 133D0BD2DF78BE7316A8FC2772C4740C
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:Background. Anemia is one of the most challenging problems in clinical oncology due to its high prevalence among the patients with malignant diseases. The purposes of our study were: (1) to assess the potential of epoetin alfa therapy to prevent the decline in Hb concentrations that typically accompanies chemotherapy/radiotherapy (ChT/RT) of the patients with rectal cancer; (2) to test the hypothesis that the use of epoetin alfa significantly reduces the transfusion requirements in the patients with rectalcancer treated with ChT/RTafter surgery, and (3) to evaluate the safety profile of the administration of epoetin alfa in the clinical setting. Methods. Sixty patients who underwent surgery for rectal cancer were prospectively enrolled. Group A consisted of 39 patients with Hb concentrations <13 g/dl at the start of ChT/RT following surgery, and group B of 17 patients with Hb concentrations >13 g/dl at the start of ChT/RT following surgery, but whose Hb concentrations fell below 13 g/dl during the ChT/RT protocol. The starting dose of epoetin alfa in both proups was 10,000 IU subcutaneously (se) three times a week (tiw). The following major parameters were evaluated: (1) change in Hb concentrations relative to the baseline as measured at 4-week intervals, (2) allogenic blood transfusion requirements in relation to Hb concentrations, and (3) incidence and severity of adverse events and their potential relationship to epoetin alfa administration. (Abstract truncated at 2000 characters)
Publication status:Published
Publication version:Version of Record
Publication date:01.01.2005
Publisher:Association of Radiology and Oncology
Year of publishing:2005
Number of pages:str. 133-140
Numbering:Letn. 39, št. 2
Source:Ljubljana
PID:20.500.12556/DiRROS-18169 New window
UDC:616.3
ISSN on article:1318-2099
COBISS.SI-ID:19766745 New window
Copyright:by Authors
Note:BSDOCID115522;
Publication date in DiRROS:14.02.2024
Views:216
Downloads:72
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Radiology and oncology
Shortened title:Radiol. oncol.
Publisher:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 New window

Secondary language

Language:Slovenian
Title:[Zdravljenje anemije z epoetinom alfa pri bolnikih z rakom danke]
Abstract:Izhodišča. Anemija, ki povzroča zmanjšanje funkcionalne zmogljivosti in kakovosti bolnikovega življenja, je pogosto spremljevalka raka. V klinični raziskavi smo želeli ugotoviti, ali lahko z epoetinom alfa preprečimo padec invzdržujemo zadovoljive vrednosti hemoglobina (Hb) pri bolnikih s karcinomom danke, ki jih po operaciji zdravimo z radiokemoterapijo (RT-KT). Sledili smo tudi bolnikove potrebe po transfuziji in varnost epoetina alfa. Metode. V raziskavo smo vključili 60 bolnikov po radikalni operaciji raka danke. V skupini A je bilo 39 bolnikov s koncentracijo Hb AAA 13 g/dl ob pričetku pooperativne RT-KT, v skupini B pa 17 bolnikov s koncentracijo Hb VVV 13 g/dl ob pričetku pooperativnega zdravljenja in pri katerih je koncentracija Hb padla pod 12 g/dl v času KT-RT. Bolniki so prejemali epoetin alfa v odmerku 10.000 IE subkutano trikrat na teden. Ocenjevali smo naslednje parametre: (1) značilnost gibanja Hb med terapijo z epoetinom alfa in KT-RT, (2) delež bolnikov, ki so potrebovali transfuzijo in (3) delež bolnikov, pri katerih smoopazili neželene učinke zdravljenja z epoetinom alfa. Rezultati. Statistično smo obdelali 56/60 (93%) protokolov. Pri vseh bolnikih v skupini Aje bilo opaziti statistično pomemben porast (pZZZ0.001) Hb že po štirih tednih zdravljenja z epoetinom alfa (povprečen dvig Hb 1,97 I 0,91 g/dl). Kljub nihanju koncentracije Hb je bila ta ves čas statistično pomembno višja kot ob začetku raziskave (p=0,0017). V skupini B je bilo opaziti v prvih tednih spremljanja postopen padec koncentracije Hb, ki je dosegla v tretjem tednu statistično pomembno nižjo vrednost kot ob vključitvi v raziskavo (p=0,006). Po uvedbi epoetina alfa je bilo tudi v tej skupini bolnikov opazitinormalizacijo vrednosti Hb in ustalitev med 12-13 g/dl. Nihče od bolnikov v raziskavi ni prejel transfuzije. Nobeden od devetih opisanih neželenih učinkov pri 6 bolnikih ni bil povezan z epoetinom alfa. (Izvleček skrajšan na 2000 znakov)


Back